Physician profile
John Molina
NPI 1043622855
$38,811.41
in general payments reported to CMS, 2019-2025
9 companies · $35K in 2025
The $35K reported for 2025 was more than what 90% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.65 · 2024: $3,883 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $3,685 · Honoraria: $2,860 · Food and Beverage: $1,211 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,456.00 |
| Travel and Lodging | $3,684.52 |
| Honoraria | $2,860.00 |
| Food and Beverage | $1,210.89 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $34,664.11 | 2024-2025 | |
| Autolus INC | $3,092.31 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $400.00 | 2024 | Imfinzi |
| Sobi, INC | $228.07 | 2024 | |
| Rigel Pharmaceuticals, INC. | $148.13 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $144.37 | 2025 | Libtayo |
| Incyte Corporation | $72.07 | 2023-2025 | Jakafi |
| Syndax Pharmaceuticals, INC. | $36.19 | 2025 | |
| Amgen INC. | $26.16 | 2025 | Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.